Opral (Omeprazole Sodium)

Omeprazole sodium, the active ingredient in Opral, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children. GNH USA supplies Opral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Opral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opral is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive esophagitis: heals erosions caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances ulcer healing when used with antibiotics.

Adverse reactions to omeprazole may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests. - Acute interstitial nephritis: kidney inflammation.

When prescribing Opral, clinicians should consider several safety aspects: - Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections. - Evaluate bone health: long‑term therapy may affect calcium absorption. - Review concomitant medications: potential for altered drug absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may interact with a range of medicines, requiring careful management.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir and other protease inhibitors: decreased antiviral efficacy. - Methotrexate: increased serum levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Phenytoin: reduced plasma concentration. - Diazepam: increased serum concentration. - Digoxin: possible increase in serum levels.